drugset / Trial / NCT06281899

Summary

This is a prospective multicenter randomized controlled trial with a total duration of 36 months aiming to evaluate the effectiveness and the safety of low protein diet on top of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and renin-angiotensin-aldosterone inhibitors (RAASi) in reducing the progression of chronic kidney disease in patients with type 2 Diabetes Mellitus

Timeline

Start
2022-01-01
Primary completion
2024-12-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Background Dapagliflozin Small molecule 10 mg